Case: Patents/Obviousness (P.T.A.B.)

Challenged claims of Agilent Technologies Inc.'s patent that discloses a system for monitoring cells, which includes a device for monitoring cell-substrate impedance, aren’t unpatentable as obvious over prior art, the Patent Trial and Appeal Board said, in an inter partes review by Axion BioSystems Inc. The board said that the challenged claims aren’t obvious over prior art that discloses systems and devices for assaying cells using cell-substrate impedance monitoring, and that discloses an impedance measurement system. And the board granted Axion’s motion to strike.
This summary was produced by Bloomberg Law Automation and edited by Bloomberg Law staff.